 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...247248249250251252253254255256257...266267» |
- | Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer (clinicaltrials.gov) - May 16, 2016
P2, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed
- | Yervoy (ipilimumab) / BMS
Trial completion, Combination therapy, Metastases: Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - May 16, 2016
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk, Yervoy (ipilimumab) / BMS
Trial completion, Combination therapy, Surgery, Metastases: Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery (clinicaltrials.gov) - May 16, 2016
P1, N=19, Completed, Sponsor: University of Southern California
No longer recruiting --> Completed Suspended --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - May 15, 2016
P3, N=490, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Suspended --> Completed Trial primary completion date: Jul 2018 --> Jan 2020
- ||| lefitolimod (MGN1703) / Feng Biosci, iPharma, Gilead, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - May 13, 2016
P1, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2018 --> Jan 2020 Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> May 2016 | Trial primary completion date: Aug 2019 --> May 2019
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (clinicaltrials.gov) - May 13, 2016
P2, N=30, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> May 2016 | Trial primary completion date: Aug 2019 --> May 2019 Trial primary completion date: Jul 2017 --> Jun 2016
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen, Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial primary completion date, Metastases: IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma (clinicaltrials.gov) - May 13, 2016
P1/2, N=19, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2017 --> Jun 2016 Active, not recruiting --> Completed | N=64 --> 19 | Trial primary completion date: Feb 2017 --> May 2016
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Monotherapy: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (clinicaltrials.gov) - May 12, 2016
P3, N=1070, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=64 --> 19 | Trial primary completion date: Feb 2017 --> May 2016 Active, not recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Enrollment change, Monotherapy, Metastases: Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (clinicaltrials.gov) - May 11, 2016
P1, N=48, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting | N=30 --> 48
- ||| plozalizumab (TAK-202) / Takeda, Ojemda (tovorafenib) / Day One Biopharma, Entyvio (vedolizumab) / Takeda
Enrollment open, Checkpoint inhibition: Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (clinicaltrials.gov) - May 11, 2016
P1, N=156, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Recruiting | N=30 --> 48 Not yet recruiting --> Recruiting
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Monotherapy: CheckMate 401: Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (clinicaltrials.gov) - May 9, 2016
P3, N=615, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: GEM1402: Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma (clinicaltrials.gov) - May 9, 2016
P2, N=48, Recruiting, Sponsor: Grupo Espa
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (clinicaltrials.gov) - May 5, 2016
P2, N=100, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || lefitolimod (MGN1703) / Feng Biosci, iPharma, Gilead, Yervoy (ipilimumab) / BMS
Trial initiation date, Trial primary completion date, Metastases: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - May 4, 2016
P1, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Initiation date: Mar 2016 --> Aug 2016 | Trial primary completion date: Mar 2019 --> Aug 2019
- Tafinlar (dabrafenib) / Novartis, BeiGene, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Metastases: Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma (clinicaltrials.gov) - May 3, 2016
P1/2, N=6, Active, not recruiting, Sponsor: University of Utah
Initiation date: Mar 2016 --> Aug 2016 | Trial primary completion date: Mar 2019 --> Aug 2019 Recruiting --> Active, not recruiting | N=45 --> 6
- Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - May 3, 2016
P1, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=45 --> 6 Trial primary completion date: Mar 2016 --> Jun 2018
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - May 3, 2016
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2016 --> Jun 2018 Trial primary completion date: Apr 2016 --> Apr 2017
- ||| Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - May 3, 2016
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2016 --> Apr 2017 Recruiting --> Active, not recruiting
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, PD(L)-1 Biomarker: NCI-2016-00661: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer (clinicaltrials.gov) - May 2, 2016
P1/2, N=80, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=130 --> 80
- Yervoy (ipilimumab) / Ono Pharma, BMS
New trial, Metastases: Ipi-Lu-Tox: Ipilimumab-induced Lung Toxicity: Observational Study (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=71, Completed, Sponsor: University of Zurich
- |||||||||| Erbitux (cetuximab) / Eli Lilly, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial, PD(L)-1 Biomarker, IO biomarker: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 27, 2016
P3, N=490, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||||| New P2 trial: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 25, 2016
P2, N=685, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Phase classification, Trial primary completion date: CheckMate 511: A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Apr 25, 2016
P3b/4, N=340, Recruiting, Sponsor: Bristol-Myers Squibb
N=130 --> 80 Not yet recruiting --> Recruiting | Phase classification: P3 --> P3b/4 | Trial primary completion date: Aug 2017 --> May 2017
- Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Apr 22, 2016
P2/3, N=400, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Phase classification: P3 --> P3b/4 | Trial primary completion date: Aug 2017 --> May 2017 Trial primary completion date: Jun 2017 --> Nov 2021
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, PD(L)-1 Biomarker: Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 22, 2016
P2, N=110, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2017 --> Nov 2021 N=60 --> 110
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Monotherapy, PD(L)-1 Biomarker, IO biomarker: MAPS2: Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (clinicaltrials.gov) - Apr 21, 2016
P2, N=114, Recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
N=60 --> 110 Not yet recruiting --> Recruiting
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: J1414: Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (clinicaltrials.gov) - Apr 21, 2016
P2, N=16, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Sep 2016
- | canerpaturev (TBI-1401) / Takara
Enrollment closed, Trial primary completion date, Oncolytic virus, Metastases: A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Apr 21, 2016
P2, N=46, Active, not recruiting, Sponsor: Takara Bio Inc.
Trial primary completion date: Jan 2016 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2016
- Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Apr 21, 2016
P1, N=28, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2016 Recruiting --> Active, not recruiting | N=39 --> 28
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker, Metastases: Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=39 --> 28 Trial primary completion date: Mar 2016 --> Mar 2017
- | Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, Monotherapy: Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov) - Apr 19, 2016
P2, N=49, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2016 --> Mar 2017 N=40 --> 49 | Trial primary completion date: Aug 2014 --> Nov 2014
- | Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
New P2 trial: Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma (clinicaltrials.gov) - Apr 19, 2016
P2, N=70, Not yet recruiting, Sponsor: University of Chicago
- || Xpovio (selinexor) / Karyopharm
Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Apr 15, 2016
P1, N=470, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=40 --> 49 | Trial primary completion date: Aug 2014 --> Nov 2014 N=251 --> 470
- ||| Yervoy (ipilimumab) / Ono Pharma, BMS
New trial: Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=370, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- | Yervoy (ipilimumab) / BMS
Trial completion: The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Apr 14, 2016
P2, N=42, Completed, Sponsor: University Hospital Southampton NHS Foundation Trust.
N=251 --> 470 Active, not recruiting --> Completed
- ||||| Opdivo (nivolumab) / BMS, BMS-986178 / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, PD(L)-1 Biomarker, IO biomarker: An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Apr 14, 2016
P1/2, N=212, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || Opdivo (nivolumab) / BMS
Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Apr 13, 2016
P1/2, N=96, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Sep 2016
- | Enrollment open, PD(L)-1 Biomarker, IO biomarker: DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov) - Apr 13, 2016
P3, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Sep 2016 Suspended --> Recruiting
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Monotherapy: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (clinicaltrials.gov) - Apr 13, 2016
P3, N=1099, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Suspended --> Recruiting Recruiting --> Active, not recruiting
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, New P1/2 trial, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone (clinicaltrials.gov) - Apr 13, 2016
P1/2, N=66, Not yet recruiting, Sponsor: University of Pittsburgh
- Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-?2b for Melanoma (clinicaltrials.gov) - Apr 12, 2016
P1, N=30, Active, not recruiting, Sponsor: Ahmad Tarhini
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2018 --> Sep 2016
- Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date, Metastases: Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=13, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2018 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Nov 2016
- ||| ADU-S100 / Novartis
Enrollment open, IO biomarker, Metastases: Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas (clinicaltrials.gov) - Apr 11, 2016
P1, N=75, Recruiting, Sponsor: Aduro Biotech, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Nov 2016 Not yet recruiting --> Recruiting
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, PD(L)-1 Biomarker: Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (clinicaltrials.gov) - Apr 7, 2016
P2, N=37, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy (clinicaltrials.gov) - Apr 7, 2016
P2, N=70, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- CD19CAR-28-zeta T cells / Baylor College of Medicine
Enrollment change, Trial primary completion date: CRETI-NH: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (clinicaltrials.gov) - Mar 30, 2016
P1, N=14, Active, not recruiting, Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting N=54 --> 14 | Trial primary completion date: Feb 2018 --> Jul 2014
- ||| Imlygic (talimogene laherparepvec) / Amgen
Enrollment closed: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Mar 30, 2016
P1/2, N=217, Active, not recruiting, Sponsor: Amgen
N=54 --> 14 | Trial primary completion date: Feb 2018 --> Jul 2014 Recruiting --> Active, not recruiting
- ||| plozalizumab (TAK-202) / Takeda, Ojemda (tovorafenib) / Day One Biopharma, Entyvio (vedolizumab) / Takeda
New P1 trial, Checkpoint inhibition: Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (clinicaltrials.gov) - Mar 30, 2016
P1, N=156, Not yet recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- Xalkori (crizotinib) / Pfizer
Enrollment change, Trial termination, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 29, 2016
P1, N=14, Terminated, Sponsor: University of Utah
Recruiting --> Active, not recruiting N=62 --> 14 | Recruiting --> Terminated
- |||| Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: A Comparative Study in Chinese Subjects With Chemotherapy Na (clinicaltrials.gov) - Mar 29, 2016
P3, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
N=62 --> 14 | Recruiting --> Terminated Trial primary completion date: Sep 2019 --> Jun 2018